# AMRX catalysts: Amneal Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/amrx/catalysts

> Amneal Pharmaceuticals, Inc. (AMRX) has 2 upcoming catalysts. The next is the testosterone cypionate 75 mg topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Amneal Pharmaceuticals, Inc. |
| Ticker | AMRX (Nasdaq) |
| SEC CIK | 1723128 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/amrx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2, 2018 | [Tigecycline (tigecycline) FDA approval](https://sec-api.dev/pdufa/tigecycline) | AMRX |  | completed, approved | "NDA211158 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180802, review_priority STANDARD; sponsor_name AMNEAL; product TIGECYCLINE (TIGECYCLINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211158%22)) |
| April 24, 2020 | [Ongentys (opicapone) FDA approval](https://sec-api.dev/pdufa/opicapone) | AMRX |  | completed, approved | "NDA212489 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200424, review_priority STANDARD; sponsor_name AMNEAL; product ONGENTYS (OPICAPONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212489%22)) |
| April 13, 2022 | [MVASI® (bevacizumab) FDA approval](https://sec-api.dev/pdufa/bevacizumab) | AMRX |  | completed, approved | "On April 13, 2022, the FDA approved our biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm)) |
| July 26, 2024 | [Potassium Phosphates In 0.9% Sodium Chloride (potassium phosphate, dibasic; potassium phosphate, monobasic) FDA approval](https://sec-api.dev/pdufa/dibasic-monobasic) | AMRX |  | completed, approved | "NDA218343 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20240726, review_priority STANDARD; sponsor_name AMNEAL; product POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218343%22)) |
| August 7, 2024 | [CREXONT (crexont) FDA approval](https://sec-api.dev/pdufa/crexont) | AMRX |  | completed, approved | "On August 7, 2024, the FDA approved the Company's new drug application for CREXONT®" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/amrx-20240930.htm)) |
| August 7, 2024 | [IPX203 FDA approval](https://sec-api.dev/pdufa/ipx203) | AMRX |  | completed, approved | "On August 7, 2024, the FDA approved our new drug application ("NDA") for CREXONT®, previously referred to as IPX203." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm)) |
| October 4, 2024 | [Pyridostigmine Bromide (pyridostigmine bromide) FDA approval](https://sec-api.dev/pdufa/pyridostigmine) | AMRX |  | completed, approved | "NDA217604 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20241004, review_priority STANDARD; sponsor_name AMNEAL; product PYRIDOSTIGMINE BROMIDE (PYRIDOSTIGMINE BROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217604%22)) |
| February 28, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000009/amrx-q42024ex991.htm)) |
| May 2, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/amrx-q12025ex991.htm)) |
| May 14, 2025 | [Brekiya (Autoinjector) (dihydroergotamine mesylate) FDA approval](https://sec-api.dev/pdufa/dihydroergotamine) | AMRX |  | completed, approved | "NDA215400 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250514, review_priority STANDARD; sponsor_name AMNEAL; product BREKIYA (AUTOINJECTOR) (DIHYDROERGOTAMINE MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215400%22)) |
| July 16, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS CERTAIN PRELIMINARY SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/amrx-q22025x8xkxpreannounc.htm)) |
| July 22, 2025 | [Lanreotide complete response letter (CRL)](https://sec-api.dev/pdufa/lanreotide) | AMRX |  | completed, complete response letter | "For 2025, asset impairment charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)) |
| August 5, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/amrx-q22025ex991.htm)) |
| Sep 2025 | [Xolair® (omalizumab) NDA/BLA submission](https://sec-api.dev/pdufa/omalizumab) | AMRX |  | completed | "In September 2025, we submitted a BLA to the FDA for our omalizumab biosimilar candidate." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)) |
| September 30, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "For the three months ended September 30, 2025 and the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm)) |
| Q4 2025 | [Xolair® (omalizumab) NDA/BLA submission](https://sec-api.dev/pdufa/omalizumab) | AMRX |  | scheduled | "Finally, we look forward to an expected BLA submission for a proposed biosimilar to XOLAIR® in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/amrx-q22025x8xkxpreannounc.htm)) |
| October 30, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/amrx-q32025ex991.htm)) |
| December 22, 2025 | [Boncresa (boncresa) FDA approval](https://sec-api.dev/pdufa/boncresa) | AMRX |  | completed, approved | "Subsequently, on December 22, 2025, we received FDA approval for both products, which will be marketed under the names Boncresa™ and Oziltus™, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)) |
| December 31, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "(4)For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-q22026ex991.htm)) |
| February 27, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/amrx-q42025ex991.htm)) |
| Apr 2026 | [Xolair® (omalizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/omalizumab) | AMRX |  | completed | "Pursuant to a license and commercialization agreement with Kashiv to distribute and sell Omalizumab, a biosimilar to XOLAIR®, in the U.S. and India, we paid Kashiv $10.0 million in April 2026 upon FDA acceptance of the biologics license application (BLA) for review." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000020/amrx-20260331.htm)) |
| April 22, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm)) |
| May 7, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/amrx-q12026ex991.htm)) |
| July 9, 2026 | [Sodium Bicarbonate (sodium bicarbonate) FDA approval](https://sec-api.dev/pdufa/bicarbonate) | AMRX |  | completed, approved | "NDA220790 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260709, review_priority STANDARD; sponsor_name AMNEAL; product SODIUM BICARBONATE (SODIUM BICARBONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220790%22)) |
| July 30, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-q22026ex991.htm)) |
| November 3, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)) |
| Mar to Jun 2027 | [Testosterone cypionate 75 mg topline data readout](https://sec-api.dev/pdufa/testosterone-cypionate) | AMRX | Male Hypogonadism | scheduled | "NCT07898072 (Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Amneal Pharmaceuticals, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07898072)) |
| March 2027 | [Testosterone cypionate 75 mg primary completion](https://sec-api.dev/pdufa/testosterone-cypionate) | AMRX | Male Hypogonadism | scheduled | "NCT07898072 (Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Amneal Pharmaceuticals, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07898072)) |

## Drugs

- [Boncresa (boncresa)](https://sec-api.dev/pdufa/boncresa): 
- [CREXONT (crexont)](https://sec-api.dev/pdufa/crexont): 
- [Potassium Phosphates In 0.9% Sodium Chloride (potassium phosphate, dibasic; potassium phosphate, monobasic)](https://sec-api.dev/pdufa/dibasic-monobasic): 
- [Brekiya (Autoinjector) (dihydroergotamine mesylate)](https://sec-api.dev/pdufa/dihydroergotamine): 
- [IPX203](https://sec-api.dev/pdufa/ipx203): 
- [Lanreotide](https://sec-api.dev/pdufa/lanreotide): 
- [Xolair® (omalizumab)](https://sec-api.dev/pdufa/omalizumab): 
- [Ongentys (opicapone)](https://sec-api.dev/pdufa/opicapone): 
- [Pyridostigmine Bromide (pyridostigmine bromide)](https://sec-api.dev/pdufa/pyridostigmine): 
- [Testosterone cypionate 75 mg](https://sec-api.dev/pdufa/testosterone-cypionate): Male Hypogonadism
- [Tigecycline (tigecycline)](https://sec-api.dev/pdufa/tigecycline): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/amrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMRX catalysts: Amneal Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/amrx/catalysts

```bibtex
@misc{secapidev_companies_amrx_catalysts_20261116,
  title        = {AMRX catalysts: Amneal Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/amrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_amrx_catalysts_20261116","title":"AMRX catalysts: Amneal Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/amrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
